BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 11708767)

  • 1. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection.
    Hernández Marin M; Márquez Bocalandro Y; Vallejo RV; Rodríguez Tanty C; Higginson Clark D; Pozo Peña L; Silva León C
    Prep Biochem Biotechnol; 2003 Feb; 33(1):29-38. PubMed ID: 12693813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Evaluation of a Novel ELISA for Detection of Antibodies against HTLV-I Using Chimeric Peptides.
    Mosadeghi P; Heydari-Zarnagh H
    Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):144-150. PubMed ID: 29757587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1.
    Hernández M; Rodríguez I; Pozo L; Rivero J
    Biochem Biophys Res Commun; 2001 Mar; 282(1):1-3. PubMed ID: 11263961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic mixture of synthetic peptides for the immunodiagnosis of HTLV I/II infection.
    Bocalandro YM; Marin MH; Vallejo RA; Peña LP; León CS; Martínez GR; Tanty CR; Clarke DH; Velázquez SB
    J Immunoassay Immunochem; 2004; 25(3):205-14. PubMed ID: 15461383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
    Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
    Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
    Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
    J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative analysis of the sequenced fragment of the Macaca arctoides STLV-1 env gene encoding the immunodominant region gp46 and the similar fragments in HTLV-1 (ATK) and STLV-1 from various primate species].
    Chikobava MG; Iakovleva LA; Indzhiia LV; Lapin BA
    Biull Eksp Biol Med; 1997 Jul; 124(7):92-6. PubMed ID: 9303743
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins].
    Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE
    Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
    Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
    Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
    Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.